OTLK News and Press, Outlook Therapeutics Inc. From 02/14/24

2024-02-14 08:12:17 ET More on Outlook Therapeutics Outlook stock rallies on private placement, FDA study agreement Outlook Therapeutics GAAP EPS of -$0.24 Seeking Alpha’s Quant Rating on Outlook Therapeutics Historical earnings data for Outlook Therap...

NORSE EIGHT underway with first subject dosed and additional clinical sites beginning enrollment Continue to expect planned resubmission of the ONS-5010 Biologics License Application (BLA) by the end of CY2024 Anticipate review decision from European regulators in the first half o...

ESSA Pharma Inc. (EPIX) is expected to report $-0.17 for Q1 2024 QuidelOrtho Corp Com (QDEL) is expected to report $2.01 for Q4 2023 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 Portsmouth Square, Inc. (PRSI) is expected to report for Q2 2024 Similarweb Ltd. (SMWB) ...

NORSE EIGHT clinical trial is being conducted under Special Protocol Assessment (SPA) from FDA to support expected resubmission of the ONS-5010 Biologics License Application (BLA) by the end of CY2024, if successful ISELIN, N.J., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, I...

2024-01-23 09:45:09 ET More on Outlook Therapeutics Outlook Therapeutics GAAP EPS of -$0.24 Outlook Therapeutics appoints new head of licensing and M&A Seeking Alpha’s Quant Rating on Outlook Therapeutics Historical earnings data for Outlook Therap...

Obtained clarity from U.S. Food and Drug Administration (FDA) on next steps to advance ONS-5010 NORSE EIGHT expected to commence in the first quarter of CY2024, enabling potential resubmission of the ONS-5010 Biologics License Application (BLA) by the end of CY2024 Private placements to t...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 investing in Outlook securities between December 29, 2022 and August 29, 2023 and wo...

SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a deadline is coming up in the lawsuit filed for certain investors in shares of Outlook Therapeutics, Inc. (NASDAQ: OTLK). Investors, who lost more than $200,000 with shares of Outlook Therapeutics, ...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 investing in Outlook securities between August 3, 2021 and August 29, 2023 and would...

Commencement of ONS-5010 NORSE EIGHT clinical trial targeted for first calendar quarter of 2024 Company reaffirms potential for European approval for ONS-5010 with Marketing Authorization Application (MAA) decision date anticipated in the first half of 2024 Resubmission of the ONS...